FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine. What is described is a method for preparing a high-purity drug preparation for treating degenerative-dystrophic diseases of peripheral synovial joints and spinal column. The method provides introducing L-proline, an amino acid in an amount of 10-70 g/l into aqueous chondroitin sulphate solution containing no more than 11.5% of an active ingredient, and filtering the solution at temperature 20-50°C through ZetaCarbon (Cuno) R54SLP, R51SLP, R53SLP or AKS (Pall) - AKS 1, 2, 6, 7 filters.
EFFECT: method provides preparing the high-grade 99% pure liquid or lyophilised chondroprotective preparation stabilised with L-proline with the residual content of organic purities: protein - no more than 0,2%, lipids (per 1mg of chondroitin sulphate) - no more than 0,05 mcg, bacterial endotoxins (per 1mg of chondroitin sulphate) - no more than 0,05 EU.
6 cl, 3 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
CHONDROITIN SULFATE SOLUTION FOR INTRAMUSCULAR ADMINISTRATION AND METHOD FOR ITS PREPARATION | 2015 |
|
RU2623050C2 |
METHOD FOR PRODUCING VIRUS-INACTIVATED IMMUNOGLOBULIN SOLUTIONS LOW IN RESIDUAL CAPRYLIC ACID | 2013 |
|
RU2561596C2 |
CHONDROITINASE, METHOD OF ITS PREPARING AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | 1993 |
|
RU2144833C1 |
PHARMACEUTICAL AGENT FOR ARTHRITIC DISEASES TREATMENT | 2020 |
|
RU2739746C1 |
PHARMACEUTICAL PREPARATION FOR TREATMENT OF ARTHROLOGICAL DISEASES | 2015 |
|
RU2743274C2 |
METHOD FOR PRODUCING SERRATIA MARCESCENS RECOMBINANT ENDONUCLEASE | 2021 |
|
RU2795623C2 |
METHOD OF PREPARING THE COMPLEX PREPARATION CONTAINING MUCOPOLYSACCHARIDES AND COLLAGEN FROM ANIMAL RAW | 1993 |
|
RU2082416C1 |
METHOD OF PRODUCING CHONDROITIN SULPHATE FROM SEA HYDROBIONT TISSUE | 2010 |
|
RU2458134C1 |
METHOD FOR PREPARING CONCENTRATED IMMUNOGLOBULIN PREPARATION FOR SUBCUTANEOUS APPLICATION | 2012 |
|
RU2487725C1 |
METHOD OF PRODUCING A RECOMBINANT NUCLEASE CAS ESSENTIALLY FREE OF BACTERIAL ENDOTOXINS, THE PREPARATION OBTAINED BY THIS METHOD AND CONTAINING A KIT FOR USE IN A CRISPR/Cas SYSTEM | 2019 |
|
RU2707542C1 |
Authors
Dates
2015-04-10—Published
2013-04-09—Filed